http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2679302-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d584042a524740a406723fe1631e49e5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B6-03 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K103-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B6-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M36-00 |
| filingDate | 2017-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02b733591306b04382eb874bc0dfc6ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79d0986f88c4cc1401ca4ab4cfa6b7fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52294b558e0cc1f8d42e82f44dbd98f2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4798285530dbe0e17c57ea1c7f32b791 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fd73c5a30cf350ef06cf70dfa09f811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1c6d3d4f20320cf4edf373f9d000047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e6f7855cc6bd9e5c308d7e5983a4802 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69ae6bf55645be11a74dc2b79b7ed89d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c8dadd73680a5492e0887dd1058148b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37f0481b09865035e1b1559b684ab946 |
| publicationDate | 2019-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2679302-C1 |
| titleOfInvention | Method for assessing the regional spread of breast cancer by single-photon emission computer tomography |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, namely to oncology and radiation diagnostics, and can be used to assess the regional prevalence of breast cancer using single-photon emission computed tomography. Radiopharmaceutical is made just before its intravenous administration. To do this, 4 ml of sodium pertechnetate Na 99m TcO 4 is injected under aseptic conditions with a syringe from the generator to the reagent vial. Composition of the reagent is as follows: 1-thio-D-glucose sodium salt hydrate - 0.625 mg, tin 2-water dichloride - 0.044–0.052 mg, ascorbic acid - not more than 0.125 mg, sodium chloride 8.0–10.0 mg, water for injection - up to 1 ml. Contents of the vial is mixed by shaking and incubated at room temperature for 30 minutes until complete dissolution of the reagent. Resulting radiopharmaceutical is injected on the basis of technetium-99m labelled derivative of glucose at a dose of 500 MBq. 40 minutes after radiopharmaceutical injection, single-photon emission computed tomography is performed on a two-detector gamma camera. Resulting images are post-processed. Metastatic lesion of regional lymph nodes is diagnosed when imaging radiotherapy sites of radiopharmaceuticals in axillary regions. n EFFECT: method provides improved accuracy and informative assessment of regional prevalence of breast cancer through the use of radiopharmaceuticals based on technetium-99m labelled derived of glucose and single-photon emission computed tomography. n 1 cl, 1 dwg, 1 tbl, 1 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2700105-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2751103-C1 |
| priorityDate | 2017-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 65.